Hikma Raises Expectations For 2021 After A Host Of Launches
Expects Uptick For Advair Rival In H2 As Vascepa Generic Gradually Gains Share
On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.
